BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143:854-859. [PMID: 17638728 DOI: 10.1001/archderm.143.7.854] [Cited by in Crossref: 322] [Cited by in F6Publishing: 215] [Article Influence: 23.0] [Reference Citation Analysis]
Number Citing Articles
1 Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-romero PL, Karpova MB, Zipser MC, Muniesa C, García-muret MP, Estrach T, Salido M, Sánchez-schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Solé F, Pujol RM, Espinet B. Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. Journal of Investigative Dermatology 2010;130:1126-35. [DOI: 10.1038/jid.2009.306] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
2 Lee WJ, Won KH, Won CH, Chang SE, Choi JH, Moon KC, Park CS, Huh J, Suh C, Lee MW. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage. Br J Dermatol 2015;173:134-45. [PMID: 25556641 DOI: 10.1111/bjd.13582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ghazawi FM, Netchiporouk E, Rahme E, Tsang M, Moreau L, Glassman S, Provost N, Gilbert M, Jean S, Pehr K, Sasseville D, Litvinov IV. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy: CTCL Incidence and Mortality in Canada. Cancer 2017;123:3550-67. [DOI: 10.1002/cncr.30758] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
4 Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. Current Opinion in Oncology 2012;24:S1-S10. [DOI: 10.1097/01.cco.0000410158.56500.c4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
5 Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Journal of the American Academy of Dermatology 2014;70:205.e1-205.e16. [DOI: 10.1016/j.jaad.2013.07.049] [Cited by in Crossref: 162] [Cited by in F6Publishing: 106] [Article Influence: 23.1] [Reference Citation Analysis]
6 Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA Jr, Kim YH. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol 2019;20:1160-70. [PMID: 31253572 DOI: 10.1016/S1470-2045(19)30320-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 20] [Article Influence: 28.0] [Reference Citation Analysis]
7 Heng YK, Koh MJA, Giam YC, Tang MBY, Chong WS, Tan SH. Pediatric Mycosis Fungoides in Singapore: A Series of 46 Children. Pediatric Dermatology 2014;31:477-82. [DOI: 10.1111/pde.12352] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
8 Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 1: Klassifikation und Diagnostik (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017;15:1266-73. [PMID: 29228489 DOI: 10.1111/ddg.13372_g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R. Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012. JCO 2012;30:4091-7. [DOI: 10.1200/jco.2011.39.8065] [Cited by in Crossref: 60] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
10 Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis: Long-term treatment of CTCL with ECP. Photodermatol Photoimmunol Photomed 2012;28:250-7. [DOI: 10.1111/j.1600-0781.2012.00689.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
12 Nthumba PM, Cavadas PC, Landin L. Primary cutaneous malignancies in sub-Saharan Africa. Ann Plast Surg 2011;66:313-20. [PMID: 21233701 DOI: 10.1097/SAP.0b013e3181e7db9a] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
13 Fitzpatrick MJ, Sayed S, Moloo Z, Kayembe MKA, Roberts DJ, Pham TA, Xi L, Raffeld M, Louissaint A, Sohani AR. Clinicopathologic Features of Peripheral T-Cell Lymphoma in Sub-Saharan Africa. Am J Clin Pathol 2021;156:42-55. [PMID: 33527979 DOI: 10.1093/ajcp/aqaa201] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Rev Anticancer Ther 2021;21:1017-28. [PMID: 33554707 DOI: 10.1080/14737140.2021.1882859] [Reference Citation Analysis]
15 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 72] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
16 Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res 2010;2:53-9. [PMID: 21188096 DOI: 10.2147/cmar.s5009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371:945-957. [PMID: 18342689 DOI: 10.1016/s0140-6736(08)60420-1] [Cited by in Crossref: 176] [Cited by in F6Publishing: 42] [Article Influence: 13.5] [Reference Citation Analysis]
18 Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs 2012;16:195-204. [PMID: 22459529 DOI: 10.1188/12.CJON.195-204] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
19 Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma 2013;54:514-9. [PMID: 22891708 DOI: 10.3109/10428194.2012.720372] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
20 Morris JC, Waldmann TA, Janik JE. Receptor-directed therapy of T-cell leukemias and lymphomas. J Immunotoxicol 2008;5:235-48. [PMID: 18569395 DOI: 10.1080/15476910802129661] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
21 Liu WP, Song YQ, Zheng W, Wang XP, Ding N, Zhu J. Aggressive Behavior and Elevated Lactate Dehydrogenase at Baseline Confer Inferior Prognosis in Patients With Primary Cutaneous Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2013;13:534-40. [DOI: 10.1016/j.clml.2013.04.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Reference Citation Analysis]
23 Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A. Sézary Syndrome: Clinical and Biological Aspects. Curr Hematol Malig Rep 2016;11:468-79. [DOI: 10.1007/s11899-016-0351-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
24 Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27:5410-5417. [PMID: 19826128 DOI: 10.1200/jco.2008.21.6150] [Cited by in Crossref: 522] [Cited by in F6Publishing: 219] [Article Influence: 43.5] [Reference Citation Analysis]
25 Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015;125:71-81. [DOI: 10.1182/blood-2014-07-588236] [Cited by in Crossref: 117] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]
26 Belloni B, Johansen N, Glass LF, Dummer R. Recent Advances in the Management of Cutaneous Lymphomas. Seminars in Oncology 2012;39:150-62. [DOI: 10.1053/j.seminoncol.2012.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Poligone B, Heald P. Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatol Clin 2010;28:501-10. [PMID: 20510760 DOI: 10.1016/j.det.2010.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Espinet B, Salgado R. Mycosis fungoides and Sézary syndrome. Methods Mol Biol 2013;973:175-88. [PMID: 23412790 DOI: 10.1007/978-1-62703-281-0_11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chen W, Mempel M, Traidl-Hofmann C, Al Khusaei S, Ring J. Gender aspects in skin diseases. J Eur Acad Dermatol Venereol. 2010;24:1378-1385. [PMID: 20384686 DOI: 10.1111/j.1468-3083.2010.03668.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
30 Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W. Interleukin-16 as a marker of Sézary syndrome onset and stage. J Clin Immunol 2011;31:39-50. [PMID: 20878214 DOI: 10.1007/s10875-010-9464-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
31 Cardwell LA, Majerowski J, Chiu YE, Harrington AM, Sokumbi O. Post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified in a pediatric patient. J Cutan Pathol 2021;48:706-12. [PMID: 33476057 DOI: 10.1111/cup.13967] [Reference Citation Analysis]
32 Ware OR, Guiyab J, Okoye GA. Phototherapy in Skin of Color. Dermatol Clin 2020;38:63-9. [PMID: 31753193 DOI: 10.1016/j.det.2019.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: A case series of 34 patients. Journal of the American Academy of Dermatology 2014;71:1117-26. [DOI: 10.1016/j.jaad.2014.07.049] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
34 Geskin LJ, Akilov OE, Lin Y, Lokshin AE. Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma. Exp Dermatol 2014;23:598-600. [PMID: 24862743 DOI: 10.1111/exd.12455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
35 Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010;16:2106-14. [PMID: 20233883 DOI: 10.1158/1078-0432.CCR-09-2879] [Cited by in Crossref: 58] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
36 Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R, Muccio DD, Eto I, Elmets CA, Garvey WT, Chang PL. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci 2018;90:343-56. [PMID: 29599065 DOI: 10.1016/j.jdermsci.2018.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
37 Eide MJ, Weinstock MA. Epidemiology of Skin Cancer. Cancer of the Skin. Elsevier; 2011. pp. 44-55. [DOI: 10.1016/b978-1-4377-1788-4.00005-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18:5051-5060. [PMID: 22850569 DOI: 10.1158/1078-0432.ccr-12-0604] [Cited by in Crossref: 174] [Cited by in F6Publishing: 42] [Article Influence: 19.3] [Reference Citation Analysis]
39 Stadler R, Assaf C, Klemke C, Nashan D, Weichenthal M, Dummer R, Sterry W. Brief S2k guidelines - Cutaneous lymphomas: Cutaneous lymphomas. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013;11:19-28. [DOI: 10.1111/ddg.12015_5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 2.9] [Reference Citation Analysis]
40 Argnani L, Broccoli A, Zinzani PL. Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev 2017;61:61-9. [PMID: 29102679 DOI: 10.1016/j.ctrv.2017.10.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
41 Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 2014;123:1159-66. [DOI: 10.1182/blood-2013-09-525915] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
42 Cao X, Shen D, Callanan DG, Mochizuki M, Chan CC. Diagnosis of systemic metastatic retinal lymphoma. Acta Ophthalmol 2011;89:e149-54. [PMID: 19958292 DOI: 10.1111/j.1755-3768.2009.01797.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
43 Janiga J, Kentley J, Nabhan C, Abdulla F. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2018;59:562-77. [PMID: 29308723 DOI: 10.1080/10428194.2017.1347650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
44 Shah KK, Pritt BS, Alexander MP. Histopathologic review of granulomatous inflammation. J Clin Tuberc Other Mycobact Dis 2017;7:1-12. [PMID: 31723695 DOI: 10.1016/j.jctube.2017.02.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 17.3] [Reference Citation Analysis]
45 Zic JA. Controversies in the management of the cutaneous T cell lymphomas. Dermatologic Therapy 2009;22:407-17. [DOI: 10.1111/j.1529-8019.2009.01257.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Holahan HM, Farah RS, Fitz S, Mott SL, Ferguson NN, Mckillip J, Link B, Liu V. Health-related quality of life in patients with cutaneous T-cell lymphoma? Int J Dermatol 2018;57:1314-9. [DOI: 10.1111/ijd.14132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
47 Nanda A, AlSaleh QA, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, Demierre MF. Mycosis fungoides in Arab children and adolescents: a report of 36 patients from Kuwait. Pediatr Dermatol 2010;27:607-13. [PMID: 21138468 DOI: 10.1111/j.1525-1470.2010.01129.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
48 Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort. Journal of the American Academy of Dermatology 2015;72:276-85. [DOI: 10.1016/j.jaad.2014.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
49 Wilcox RA. Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management: Cutaneous T-Cell Lymphoma. Am J Hematol 2014;89:837-51. [DOI: 10.1002/ajh.23756] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
50 Cho-Vega JH, Tschen JA, Duvic M, Vega F. Early-stage mycosis fungoides variants: case-based review. Ann Diagn Pathol. 2010;14:369-385. [PMID: 20850703 DOI: 10.1016/j.anndiagpath.2010.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
51 Olsen EA. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma. Dermatol Clin 2015;33:643-54. [PMID: 26433839 DOI: 10.1016/j.det.2015.06.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
52 Bhat TS, Herbosa CM, Rosenberg AR, Sogade O, Jeffe DB, Mehta-Shah N, Semenov YR, Musiek AC. Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma. Br J Dermatol 2021;184:310-8. [PMID: 32510571 DOI: 10.1111/bjd.19298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
53 Herro E, Dicaudo DJ, Davis MD, Weaver AL, Swanson DL. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009;61:271-5. [PMID: 19481294 DOI: 10.1016/j.jaad.2009.03.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
54 Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064-5073. [PMID: 19279331 DOI: 10.1182/blood-2008-10-184168] [Cited by in Crossref: 399] [Cited by in F6Publishing: 256] [Article Influence: 33.3] [Reference Citation Analysis]
55 Hymes KB. The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2010;10:98-109. [DOI: 10.3816/clml.2010.n.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
56 Chang TW, Weaver AL, Shanafelt TD, Habermann TM, Wriston CC, Cerhan JR, Call TG, Brewer JD. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. Int J Dermatol 2017;56:1125-9. [PMID: 28685851 DOI: 10.1111/ijd.13653] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sun G, Berthelot C, Li Y, Glass DA 2nd, George D, Pandya A, Kurzrock R, Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 2009;60:231-5. [PMID: 19026464 DOI: 10.1016/j.jaad.2008.09.063] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
58 Kim M, Thompson LA, Wenger SD, O'bryant CL. Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma. Ann Pharmacother 2012;46:1340-8. [DOI: 10.1345/aph.1r036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
59 Virmani P, Levin L, Myskowski PL, Flores E, Marchetti MA, Lucas AS, Pulitzer M, Horwitz S, Trippett T, Moskowitz A, Querfeld C. Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides. Pediatr Dermatol 2017;34:547-53. [PMID: 28804919 DOI: 10.1111/pde.13226] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
60 Johnson WT, Kartan S, Sokol K, Nikbakht N, Porcu P. Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial. Leukemia & Lymphoma 2021;62:1877-83. [DOI: 10.1080/10428194.2021.1888376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Gross AM, Turner J, Kirkorian AY, Okoye GA, Luca DC, Bornhorst M, Jacobs SS, Williams KM, Schore RJ. A Pediatric Case of Transformed Mycosis Fungoides in a BRCA2 Positive Patient. Journal of Pediatric Hematology/Oncology 2020;42:e361-4. [DOI: 10.1097/mph.0000000000001481] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Litvinov IV, Netchiporouk E, Cordeiro B, Doré MA, Moreau L, Pehr K, Gilbert M, Zhou Y, Sasseville D, Kupper TS. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clin Cancer Res 2015;21:2820-9. [PMID: 25779945 DOI: 10.1158/1078-0432.CCR-14-3322] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
63 Fahy CM, Fortune A, Quinn F, McMenamin ME, Browne PV, Langabeer S, McCarron S, Hayden P, Marren P, Ni Chonghaile M, Irvine AD, Vandenberghe E, Barnes L. Development of mycosis fungoides after bone marrow transplantation for chronic myeloid leukaemia: transmission from an allogeneic donor. Br J Dermatol 2014;170:462-7. [PMID: 24116988 DOI: 10.1111/bjd.12647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
65 Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75-89. [PMID: 22457602 DOI: 10.2147/CMAR.S9660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
66 Welborn M, Duvic M. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Am J Clin Dermatol 2019;20:115-22. [DOI: 10.1007/s40257-018-0402-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
67 Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin Selectively Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines and Patients’ PBMCs: Potential Role for STAT-3 and NF-κB Signaling. Journal of Investigative Dermatology 2010;130:2110-9. [DOI: 10.1038/jid.2010.86] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
68 Zampella JG, Hinds GA. Racial differences in mycosis fungoides: A retrospective study with a focus on eosinophilia. Journal of the American Academy of Dermatology 2013;68:967-71. [DOI: 10.1016/j.jaad.2012.11.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
69 Hodak E, Amitay-laish I, Feinmesser M, Davidovici B, David M, Zvulunov A, Pavlotsky F, Yaniv I, Avrahami G, Ben-amitai D. Juvenile mycosis fungoides: Cutaneous T-cell lymphoma with frequent follicular involvement. Journal of the American Academy of Dermatology 2014;70:993-1001. [DOI: 10.1016/j.jaad.2013.12.029] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
70 Hinds GA, Alhariri J, Klein RQ, Wilson LD. Treatment of mycosis fungoides with total skin electron beam: response and relapse by ethnicity and sex. Am J Clin Oncol 2013;36:481-5. [PMID: 22706179 DOI: 10.1097/COC.0b013e31825494d3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, Eich HT, Follmann M, Grabbe S, Hillen U, Klapper W, Klemke CD, Lamos C, Loquai C, Meiß F, Mestel D, Nashan D, Nicolay JP, Oschlies I, Schlaak M, Stoll C, Vag T, Weichenthal M, Wobser M, Stadler R. S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 1: Classification and Diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017;15:1266-73. [PMID: 29193659 DOI: 10.1111/ddg.13372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Fatemi Naeini F, Abtahi-Naeini B, Sadeghiyan H, Nilforoushzadeh MA, Najafian J, Pourazizi M. Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study. J Skin Cancer 2015;2015:306543. [PMID: 25694829 DOI: 10.1155/2015/306543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
73 Trager MH, Geskin LJ. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma. G Ital Dermatol Venereol 2019;154:681-95. [PMID: 31859467 DOI: 10.23736/S0392-0488.19.06503-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Evans KG, Troxel AB, Denardo BJ, Introcaso CE, Rook AH, Kim EJ. Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome. Journal of the American Academy of Dermatology 2011;64:682-9. [DOI: 10.1016/j.jaad.2009.01.044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 . Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Litvinov IV, Cordeiro B, Huang Y, Zargham H, Pehr K, Doré MA, Gilbert M, Zhou Y, Kupper TS, Sasseville D. Ectopic expression of cancer-testis antigens in cutaneous T-cell lymphoma patients. Clin Cancer Res 2014;20:3799-808. [PMID: 24850846 DOI: 10.1158/1078-0432.CCR-14-0307] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
77 Litvinov IV, Cordeiro B, Fredholm S, Ødum N, Zargham H, Huang Y, Zhou Y, Pehr K, Kupper TS, Woetmann A, Sasseville D. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle 2014;13:2975-82. [PMID: 25486484 DOI: 10.4161/15384101.2014.947759] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
78 Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clinical Lymphoma Myeloma and Leukemia 2016;16:637-43. [DOI: 10.1016/j.clml.2016.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
79 Luna RM, Körmendy D, Brunner-Weinzierl MC. Female-biased incidence of experimental autoimmune encephalomyelitis reflects sexually dimorphic expression of surface CTLA-4 (CD152) on T lymphocytes. Gend Med 2010;7:296-308. [PMID: 20869630 DOI: 10.1016/j.genm.2010.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
80 Lansigan F, Choi J, Foss FM. Cutaneous T-cell Lymphoma. Hematology/Oncology Clinics of North America 2008;22:979-96. [DOI: 10.1016/j.hoc.2008.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
81 Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas. Crit Rev Oncol Hematol 2016;99:228-40. [PMID: 26811014 DOI: 10.1016/j.critrevonc.2015.12.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
82 Park HS, McIntosh L, Braschi-Amirfarzan M, Shinagare AB, Krajewski KM. T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. Korean J Radiol 2017;18:71-83. [PMID: 28096719 DOI: 10.3348/kjr.2017.18.1.71] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
83 Riou-Gotta MO, Fournier E, Mermet I, Pelletier F, Humbert P, Danzon A, Aubin F. Primary cutaneous lymphomas: a population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003. Leuk Lymphoma 2008;49:1537-44. [PMID: 18766967 DOI: 10.1080/10428190802136368] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
84 Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol 2009;60:39-50. [PMID: 18842323 DOI: 10.1016/j.jaad.2008.08.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
85 Laws PM, Shear NH, Pope E. Childhood mycosis fungoides: experience of 28 patients and response to phototherapy. Pediatr Dermatol. 2014;31:459-464. [PMID: 24916067 DOI: 10.1111/pde.12338] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 5.6] [Reference Citation Analysis]
86 Ilieva Y, Kaloyanov K, Yosifov D, Robev B, Zhelezova I, Genova M, Mihova A, Balatzenko G, Zaharieva MM, Berger MR, Konstantinov SM. Antineoplastic potential of curcumin (cooperative study in Bulgaria and Germany). Phytochem Rev 2014;13:459-69. [DOI: 10.1007/s11101-014-9351-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
87 Humme D, Haider A, Möbs M, Mitsui H, Suárez-Fariñas M, Ohmatsu H, Isabell Geilen C, Eberle J, Krueger JG, Beyer M, Hummel M, Anagnostopoulos I, Sterry W, Assaf C. Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target. J Invest Dermatol 2015;135:2292-300. [PMID: 25848977 DOI: 10.1038/jid.2015.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
88 Poppe H, Kerstan A, Böckers M, Goebeler M, Geissinger E, Rosenwald A, Hamm H. Childhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype: CD8/CD56+ childhood MF. J Cutan Pathol 2015;42:258-64. [DOI: 10.1111/cup.12452] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
89 Pulitzer M, Myskowski PL, Horwitz SM, Querfeld C, Connolly B, Li J, Murali R. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology 2014;46:610-6. [PMID: 25393251 DOI: 10.1097/PAT.0000000000000166] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
90 Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma 2018;59:880-7. [PMID: 28853310 DOI: 10.1080/10428194.2017.1361022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
91 Dobos G, Pohrt A, Ram-Wolff C, Lebbé C, Bouaziz JD, Battistella M, Bagot M, de Masson A. Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. Cancers (Basel) 2020;12:E2921. [PMID: 33050643 DOI: 10.3390/cancers12102921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
92 Kim Y, Coomarasamy C, Jarrett P. The epidemiology of subcutaneous panniculitis-like alpha-beta T-cell lymphoma in New Zealand. Australas J Dermatol 2020;61:e196-9. [PMID: 31868922 DOI: 10.1111/ajd.13226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Geddes A, Savin J, White S, Gibson J. Primary cutaneous cd8-positive t-cell lymphoma: a case report of a rare and aggressive disease with oral presentation. Dental Update 2011;38:472-6. [DOI: 10.12968/denu.2011.38.7.472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Jain S, Zain J. Romidepsin in the treatment of cutaneous T-cell lymphoma. J Blood Med 2011;2:37-47. [PMID: 22287862 DOI: 10.2147/JBM.S9649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
95 Quaglino P, Pimpinelli N, Berti E, Calzavara-pinton P, Alfonso Lombardo G, Rupoli S, Alaibac M, Bottoni U, Carbone A, Fava P, Fimiani M, Mamusa AM, Titli S, Zinzani PL, Bernengo MG; on behalf of the Gruppo Italiano Linfomi Cutanei (GILC). Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: A multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012;118:5830-9. [DOI: 10.1002/cncr.27627] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
96 Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR. Sézary syndrome: A study of 176 patients at Mayo Clinic. Journal of the American Academy of Dermatology 2012;67:1189-99. [DOI: 10.1016/j.jaad.2012.04.043] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
97 Yosifov DY, Kaloyanov KA, Guenova ML, Prisadashka K, Balabanova MB, Berger MR, Konstantinov SM. Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leuk Res 2014;38:49-56. [PMID: 24225136 DOI: 10.1016/j.leukres.2013.10.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
98 Clough L, Bayakly AR, Ward KC, Khan MK, Chen SC, Lechowicz MJ, Flowers CR, Allen PB, Switchenko JM. Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia. Cancer 2020;126:1700-7. [PMID: 31943154 DOI: 10.1002/cncr.32665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
99 Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010;70:273-86. [PMID: 20166766 DOI: 10.2165/11532190-000000000-00000] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
100 Tronnier M. Foreign-body-associated granulomatous slack skin in folliculotropic mycosis fungoides of childhood. Journal of Cutaneous Pathology 2009;36:578-81. [DOI: 10.1111/j.1600-0560.2008.01072.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
101 Abbott R, Whittaker S, Morris S, Russell-jones R, Hung T, Bashir S, Scarisbrick J. Bexarotene therapy for mycosis fungoides and Sézary syndrome. British Journal of Dermatology 2009;160:1299-307. [DOI: 10.1111/j.1365-2133.2009.09037.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
102 van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS, Grulich AE, Giles GG, Vajdic CM. Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006: Lymphoid Neoplasms in Australia 1982-2006. Int J Cancer 2014;135:2146-56. [DOI: 10.1002/ijc.28849] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
103 Xia FD, Ferket BS, Huang V, Stern RS, Wu PA. Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: A comparative decision analysis model in the United States. Journal of the American Academy of Dermatology 2019;80:485-492.e4. [DOI: 10.1016/j.jaad.2018.07.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
104 Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 2015;4:1440-7. [PMID: 26136403 DOI: 10.1002/cam4.472] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
105 Kempf W, Kazakov DV, Belousova IE, Mitteldorf C, Kerl K. Paediatric cutaneous lymphomas: a review and comparison with adult counterparts. J Eur Acad Dermatol Venereol 2015;29:1696-709. [PMID: 25715748 DOI: 10.1111/jdv.13044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
106 Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155:150-66. [PMID: 21883142 DOI: 10.1111/j.1365-2141.2011.08852.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 71] [Article Influence: 9.1] [Reference Citation Analysis]
107 Kaul S, Belzberg M, Hughes JM, Mahadevan V, Khanna R, Bakhshi PR, Hong MS, Williams KA, Grossberg AL, Kwatra SG, Sweren RJ. Comorbidities in Mycosis Fungoides and Racial Differences in Co-Existent Lymphomatoid Papulosis: A Cross-Sectional Study of 580 Patients in an Urban Tertiary Care Center. Medicines (Basel) 2019;7:E1. [PMID: 31888015 DOI: 10.3390/medicines7010001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
108 Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R. Revisiting Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides. International Journal of Radiation Oncology*Biology*Physics 2011;81:e651-7. [DOI: 10.1016/j.ijrobp.2011.01.023] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
109 Booher S, Mccann SA, Tawa MC. Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Sézary Syndrome, Part 2. Journal of the Dermatology Nurses' Association 2011;3:75-83. [DOI: 10.1097/jdn.0b013e318211ff2e] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
110 Huang Y, Litvinov IV, Wang Y, Su MW, Tu P, Jiang X, Kupper TS, Dutz JP, Sasseville D, Zhou Y. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. Oncotarget 2014;5:4418-25. [PMID: 24947046 DOI: 10.18632/oncotarget.2031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
111 Hughes CF, Newland K, Mccormack C, Lade S, Prince HM. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers: Mycosis fungoides and Sézary syndrome. Australasian Journal of Dermatology 2016;57:182-91. [DOI: 10.1111/ajd.12349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
112 Arafah M, Zaidi SN, Kfoury HK, Al Rikabi A, Al Ghamdi K. The Histological Spectrum of Early Mycosis Fungoides: A Study of 58 Saudi Arab patients. Oman Med J 2012;27:134-9. [PMID: 22496939 DOI: 10.5001/omj.2012.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
113 Vilar Coromina N, Marcos-Gragera R. [Primary cutaneous lymphomas. Population-based incidence and survival, 1994-2004]. Med Clin (Barc) 2008;131:396-7. [PMID: 18842215 DOI: 10.1016/s0025-7753(08)72290-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Nath SK, Yu JB, Wilson LD. Poorer prognosis of African-American patients with mycosis fungoides: an analysis of the SEER dataset, 1988 to 2008. Clin Lymphoma Myeloma Leuk 2014;14:419-23. [PMID: 24508350 DOI: 10.1016/j.clml.2013.12.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
115 Scarisbrick J, Kim Y, Whittaker S, Wood G, Vermeer M, Prince H, Quaglino P. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol 2014;170:1226-36. [DOI: 10.1111/bjd.12909] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
116 Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. Journal of the American Academy of Dermatology 2015;72:286-92. [DOI: 10.1016/j.jaad.2014.10.014] [Cited by in Crossref: 99] [Cited by in F6Publishing: 49] [Article Influence: 16.5] [Reference Citation Analysis]
117 Dairi M, Dadban A, Arnault J, Lok C, Chaby G. Localized mycosis fungoides treated with laser‐assisted photodynamic therapy: a case series. Clin Exp Dermatol 2019;44:930-2. [DOI: 10.1111/ced.13936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Fu W, Yi S, Qiu L, Sun J, Tu P, Wang Y. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma. J Invest Dermatol 2017;137:1523-32. [PMID: 28288848 DOI: 10.1016/j.jid.2017.02.980] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
119 Bassuner J, Miranda RN, Emge DA, DiCicco BA, Lewis DJ, Duvic M. Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. Case Rep Dermatol Med 2016;2016:5857935. [PMID: 28074163 DOI: 10.1155/2016/5857935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
120 Romero M, Haney M, Desantis E, Zlotoff B. Mycosis Fungoides with Focal CD 30 Transformation in an Adolescent. Pediatric Dermatology 2008;25:565-8. [DOI: 10.1111/j.1525-1470.2008.00763.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
121 Han JH, Ko YH, Kang YK, Kim WS, Kim YJ, Kim I, Kim HJ, Min SK, Park CK, Park CS, Shin BK, Yang WI, Oh YH, Lee JS, Lee J, Lee TH, Lee H, Lee HJ, Jeon YK, Cha HJ, Choi YD, Kim CW; Hematopathology Study Group of the Korean Society of Pathologists. Characteristics of Cutaneous Lymphomas in Korea According to the New WHO-EORTC Classification: Report of a Nationwide Study. Korean J Pathol 2014;48:126-32. [PMID: 24868225 DOI: 10.4132/KoreanJPathol.2014.48.2.126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
122 Geller S, Lebowitz E, Pulitzer MP, Horwitz SM, Moskowitz AJ, Dusza S, Myskowski PL. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. J Am Acad Dermatol 2020;83:430-9. [PMID: 31499157 DOI: 10.1016/j.jaad.2019.08.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
123 Sattarzadeh R, Ghodsi S, Eslami M, Mollazadeh R, Safaei Nodehi R, Hosseini Z. Secondary Cardiac T-Cell Lymphoma Presenting with Syncope and Refractory Complete Atrioventricular Block: A Case Report. J Tehran Heart Cent 2020;15:183-8. [PMID: 34178088 DOI: 10.18502/jthc.v15i4.5945] [Reference Citation Analysis]
124 Trautinger F. Phototherapy of mycosis fungoides. Photodermatol Photoimmunol Photomed 2011;27:68-74. [PMID: 21392108 DOI: 10.1111/j.1600-0781.2011.00559.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
125 Hanna R, Di Primio GA, Schweitzer M, Torres C, Sheikh A, Chakraborty S. Progressive neurolymphomatosis with cutaneous disease: Response in a patient with mycosis fungoides. Skeletal Radiol 2013;42:1011-5. [DOI: 10.1007/s00256-013-1595-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
126 Sokołowska-Wojdyło M, Lugowska-Umer H, Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol 2013;30:19-29. [PMID: 24278042 DOI: 10.5114/pdia.2013.33375] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
127 Segal O, Trumper N, Pavlotsky F, Goldzweig G, Barzilai A. Illness perception, coping, and quality of life in early-stage Mycosis fungoides. An Bras Dermatol 2021;96:27-33. [PMID: 33279315 DOI: 10.1016/j.abd.2020.05.008] [Reference Citation Analysis]
128 Aschebrook-Kilfoy B, Cocco P, La Vecchia C, Chang ET, Vajdic CM, Kadin ME, Spinelli JJ, Morton LM, Kane EV, Sampson JN, Kasten C, Feldman AL, Wang SS, Zhang Y. Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014;2014:98-105. [PMID: 25174030 DOI: 10.1093/jncimonographs/lgu008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
129 Demierre M. Mycosis fungoides and Sézary syndrome: the burden of pruritus. Community Oncology 2010;7:399-404. [DOI: 10.1016/s1548-5315(11)70414-4] [Cited by in Crossref: 10] [Article Influence: 0.9] [Reference Citation Analysis]
130 Pope E, Weitzman S, Ngan B, Walsh S, Morel K, Williams J, Stein S, Garzon M, Knobler E, Lieber C, Turchan K, Wargon O, Tsuchiya A. Mycosis Fungoides in the Pediatric Population: Report from an International Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg 2010;14:1-6. [DOI: 10.2310/7750.2009.08091] [Cited by in Crossref: 58] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
131 Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol. 2009;129:1115-1119. [PMID: 19242508 DOI: 10.1038/jid.2009.45] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
132 Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 2015;56:2847-54. [PMID: 25791237 DOI: 10.3109/10428194.2015.1014360] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
133 Quaglino P, Knobler R, Fierro MT, Savoia P, Marra E, Fava P, Bernengo MG. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. Int J Dermatol 2013;52:1308-18. [PMID: 23786842 DOI: 10.1111/ijd.12121] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
134 Li H, Wang C, Ma P, Zhang M, Yang H, Yuan S, Wei J, Tao L, Qian K, Xu M, Li L. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway. J Dermatol Sci 2020;97:208-15. [PMID: 32165081 DOI: 10.1016/j.jdermsci.2020.01.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2020;7:CD008946. [PMID: 32632956 DOI: 10.1002/14651858.CD008946.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Drews RE. Emerging Treatment Options for Advanced-Stage Mycosis Fungoides. JCO 2012;30:4064-70. [DOI: 10.1200/jco.2012.44.5650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Jang MS, Kang DY, Park JB, Kim ST, Suh KS. Cutaneous T-cell lymphoma in asians. ISRN Dermatol 2012;2012:575120. [PMID: 22844610 DOI: 10.5402/2012/575120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
138 Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel M, Wong H, Porcu P. . CDT 2010;11:482-93. [DOI: 10.2174/138945010790980376] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
139 Lonsdorf AS, Hwang ST, Enk AH. Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol. 2009;129:2552-2566. [PMID: 19474804 DOI: 10.1038/jid.2009.122] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
140 Kaufman AE, Patel K, Goyal K, O'Leary D, Rubin N, Pearson D, Bohjanen K, Goyal A. Mycosis fungoides: developments in incidence, treatment and survival. J Eur Acad Dermatol Venereol 2020;34:2288-94. [PMID: 32141115 DOI: 10.1111/jdv.16325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
141 Cowan RA, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter-Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen JP, Medley MC. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol 2021. [PMID: 34273208 DOI: 10.1111/jdv.17523] [Reference Citation Analysis]
142 Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther 2019;12:1085-94. [PMID: 30799938 DOI: 10.2147/OTT.S165615] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 12.5] [Reference Citation Analysis]
143 Cheeley J, Sahn RE, Delong LK, Parker SR. Acitretin for the treatment of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2013;68:247-54. [DOI: 10.1016/j.jaad.2012.07.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
144 Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012;51:930-4. [PMID: 22788808 DOI: 10.1111/j.1365-4632.2011.05188.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
145 Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD. Analysis of Primary CD30+ Cutaneous Lymphoproliferative Disease and Survival From the Surveillance, Epidemiology, and End Results Database. JCO 2008;26:1483-8. [DOI: 10.1200/jco.2007.14.1374] [Cited by in Crossref: 30] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
146 Alsaleh QA, Nanda A, Al-Ajmi H, Al-Sabah H, Elkashlan M, Al-Shemmari S, Demierre MF. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991-2006. Int J Dermatol 2010;49:1393-8. [PMID: 21155090 DOI: 10.1111/j.1365-4632.2010.04567.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
147 Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, Roberts WE, Draelos ZD, Bhushan R, Taylor SC, Lim HW. Skin cancer and photoprotection in people of color: A review and recommendations for physicians and the public. Journal of the American Academy of Dermatology 2014;70:748-62. [DOI: 10.1016/j.jaad.2013.11.038] [Cited by in Crossref: 144] [Cited by in F6Publishing: 73] [Article Influence: 20.6] [Reference Citation Analysis]
148 Ohmatsu H, Humme D, Gulati N, Gonzalez J, Möbs M, Suárez-Fariñas M, Cardinale I, Mitsui H, Guttman-Yassky E, Sterry W, Krueger JG. IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization. Cancer Immunol Res 2014;2:890-900. [PMID: 24938282 DOI: 10.1158/2326-6066.CIR-13-0199-T] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
149 Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, Parmiggiani M, Barbieri P, Bertoni F. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Rep Pract Oncol Radiother 2014;19:77-91. [PMID: 24936325 DOI: 10.1016/j.rpor.2013.07.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
150 Mishra A, Porcu P. Early CTCL diagnosis, a (miR)age no more? Blood 2011;118:5717-8. [PMID: 22123905 DOI: 10.1182/blood-2011-09-379107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
151 Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma 2013;54:752-9. [PMID: 23004352 DOI: 10.3109/10428194.2012.729831] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
152 Tsang Y, Gu T, Sharma G, Raspa S, Drake B 3rd, Tan H. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat 2018;29:747-53. [PMID: 29733229 DOI: 10.1080/09546634.2018.1466026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
153 Virmani P, Hwang SH, Hastings JG, Haverkos BM, Kohnken B, Gru AA, Mishra A, Fabbro SK, Horwitz SM, Porcu P. Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Expert Review of Hematology 2017;10:111-21. [DOI: 10.1080/17474086.2017.1270201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
154 Ferenczi K, Makkar HS. Cutaneous lymphoma: Kids are not just little people. Clinics in Dermatology 2016;34:749-59. [DOI: 10.1016/j.clindermatol.2016.07.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
155 Polańska A, Osmola-mańkowska A, Olek-hrab K, Molińska-glura M, Adamski Z, Żaba R, Dańczak-pazdrowska A. High-frequency ultrasonography in objective evaluation of the efficacy of PUVA and UVA 1 phototherapy in mycosis fungoides. Arch Dermatol Res 2017;309:645-51. [DOI: 10.1007/s00403-017-1767-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
156 Fujii K. New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. Front Oncol 2018;8:198. [PMID: 29915722 DOI: 10.3389/fonc.2018.00198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
157 Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-rodriguez C, Geskin LJ. Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma 2009;9:412-6. [DOI: 10.3816/clm.2009.n.082] [Cited by in Crossref: 64] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
158 Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys 2011;508:185-91. [PMID: 21036138 DOI: 10.1016/j.abb.2010.10.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
159 Lin M, Kowolik CM, Xie J, Yadav S, Overman LE, Horne DA. Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma. Cancers (Basel) 2021;13:3367. [PMID: 34282785 DOI: 10.3390/cancers13133367] [Reference Citation Analysis]
160 VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011;64:525-531. [PMID: 21587264 DOI: 10.1038/ja.2011.35] [Cited by in Crossref: 175] [Cited by in F6Publishing: 141] [Article Influence: 17.5] [Reference Citation Analysis]
161 Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, Sterry W. Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs 2008;13:345-61. [PMID: 18537525 DOI: 10.1517/14728214.13.2.345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
162 Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk 2012;12:291-6. [PMID: 23040434 DOI: 10.1016/j.clml.2012.06.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
163 Hong CH, Lin SH, Lee CH. CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma. In Vivo 2019;33:793-800. [PMID: 31028199 DOI: 10.21873/invivo.11541] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
164 Markova A, Weinstock MA. Trends in cutaneous lymphoma epidemiology. Clin Lymphoma Myeloma Leuk 2010;10 Suppl 2:S63-6. [PMID: 20826399 DOI: 10.3816/CLML.2010.s.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
165 Castano E, Glick S, Wolgast L, Naeem R, Sunkara J, Elston D, Jacobson M. Hypopigmented mycosis fungoides in childhood and adolescence: a long-term retrospective study: Hypopigmented MF in childhood. J Cutan Pathol 2013;40:924-34. [DOI: 10.1111/cup.12217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
166 Jung JM, Lim DJ, Won CH, Chang SE, Lee MW, Lee WJ. Mycosis Fungoides in Children and Adolescents: A Systematic Review. JAMA Dermatol 2021;157:431-8. [PMID: 33656521 DOI: 10.1001/jamadermatol.2021.0083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak ® ) therapy. Future Oncology 2008;4:457-69. [DOI: 10.2217/14796694.4.4.457] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
168 Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer 2015;121:1993-2003. [PMID: 25728286 DOI: 10.1002/cncr.29301] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
169 Ghazawi FM, Alghazawi N, Le M, Netchiporouk E, Glassman SJ, Sasseville D, Litvinov IV. Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). Front Oncol 2019;9:300. [PMID: 31106143 DOI: 10.3389/fonc.2019.00300] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
170 Buhl T, Bertsch HP, Kaune KM, Mitteldorf C, Schön MP, Kretschmer L. Low-Dose Gemcitabine Efficacious in Three Patients With Tumor-Stage Mycosis Fungoides. Clinical Lymphoma and Myeloma 2009;9:E21-4. [DOI: 10.3816/clm.2009.n.079] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
171 Boix-vilanova J, Corral-magaña O, Martin-santiago A, Escalas J. Folliculotropic mycosis fungoides in a pediatric patient with response to psoralen-ultraviolet A phototherapy. Photodermatol Photoimmunol Photomed 2019;35:54-6. [DOI: 10.1111/phpp.12414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
172 Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol 2011;64:423-31. [PMID: 20692726 DOI: 10.1016/j.jaad.2009.11.692] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
173 Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome. Curr Oncol Rep 2018;20:32. [PMID: 29572582 DOI: 10.1007/s11912-018-0678-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
174 Wollina U. Cutaneous T cell lymphoma: update on treatment: Cutaneous T cell lymphoma: treatment update. International Journal of Dermatology 2012;51:1019-36. [DOI: 10.1111/j.1365-4632.2011.05337.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
175 Hinds GA, Heald P. Cutaneous T-cell lymphoma in skin of color. Journal of the American Academy of Dermatology 2009;60:359-75. [DOI: 10.1016/j.jaad.2008.10.031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
176 Phyo ZH, Shanbhag S, Rozati S. Update on Biology of Cutaneous T-Cell Lymphoma. Front Oncol 2020;10:765. [PMID: 32477957 DOI: 10.3389/fonc.2020.00765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
177 Brazzelli V, Rivetti N, Badulli C, Carugno A, Grasso V, De Silvestri A, Martinetti M, Borroni G. Immunogenetic factors in mycosis fungoides: can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients. J Eur Acad Dermatol Venereol 2014;28:1732-7. [DOI: 10.1111/jdv.12391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
178 Agi C, Kuhn D, Chung J, Zampella J, Hinds G. Racial differences in the use of extracorporeal photopheresis for mycosis fungoides. Journal of Dermatological Treatment 2015;26:266-8. [DOI: 10.3109/09546634.2014.946381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
179 Chung JS, Shiue LH, Duvic M, Pandya A, Cruz PD Jr, Ariizumi K. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 2011;117:3382-90. [PMID: 21252093 DOI: 10.1182/blood-2010-08-302034] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
180 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [DOI: 10.1002/ajh.22139] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
181 Reddy SA. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Crit Rev Oncol Hematol 2016;106:99-107. [PMID: 27637355 DOI: 10.1016/j.critrevonc.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
182 Saunes M, Lund Nilsen T, Johannesen T. Incidence of primary cutaneous T-cell lymphoma in Norway. British Journal of Dermatology 2009;160:376-9. [DOI: 10.1111/j.1365-2133.2008.08852.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
183 Weberschock T, Strametz R, Lorenz M, Röllig C, Bunch C, Bauer A, Schmitt J. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012;:CD008946. [PMID: 22972128 DOI: 10.1002/14651858.CD008946.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
184 Phan A, Veldman R, Lechowicz MJ. T-cell Lymphoma Epidemiology: the Known and Unknown. Curr Hematol Malig Rep 2016;11:492-503. [PMID: 27995419 DOI: 10.1007/s11899-016-0353-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
185 Devata S, Wilcox RA. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents. Am J Clin Dermatol 2016;17:225-37. [DOI: 10.1007/s40257-016-0177-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
186 Bonin S, Tothova SM, Barbazza R, Brunetti D, Stanta G, Trevisan G. Evidence of multiple infectious agents in mycosis fungoides lesions. Exp Mol Pathol 2010;89:46-50. [PMID: 20470773 DOI: 10.1016/j.yexmp.2010.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
187 Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008;2:717-24. [PMID: 19707452 DOI: 10.2147/btt.s3084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
188 Dalal M, Mitchell S, Mccloskey C, Zagadailov E, Gautam A. The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review. Expert Review of Hematology 2020;13:405-19. [DOI: 10.1080/17474086.2020.1717945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
189 Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter Photopheresis Intervention Trial in Early-Stage Mycosis Fungoides. Clinical Lymphoma Myeloma and Leukemia 2011;11:219-27. [DOI: 10.1016/j.clml.2011.03.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
190 Reiter O, Ben Amitai D, Amitay-laish I, Israeli M, Pavlovsky L, Hodak E. Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients. Arch Dermatol Res 2017;309:851-6. [DOI: 10.1007/s00403-017-1783-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Brazzelli V, Bernacca C, Segal A, Barruscotti S, Bolcato V, Michelerio A, Tomasini CF. Photo-photochemotherapy in Juvenile-onset Mycosis Fungoides: A Retrospective Study on 9 Patients. J Pediatr Hematol Oncol 2019;41:34-7. [PMID: 30130275 DOI: 10.1097/MPH.0000000000001277] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Stephen S, Kim EJ, Introcaso CE, Richardson SK, Rook AH. Cutaneous T-Cell Lymphoma. In: Gaspari AA, Tyring SK, Kaplan DH, editors. Clinical and Basic Immunodermatology. Cham: Springer International Publishing; 2017. pp. 715-40. [DOI: 10.1007/978-3-319-29785-9_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
193 Querfeld C, Leung S, Myskowski PL, Curran SA, Goldman DA, Heller G, Wu X, Kil SH, Sharma S, Finn KJ, Horwitz S, Moskowitz A, Mehrara B, Rosen ST, Halpern AC, Young JW. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 2018;6:900-9. [PMID: 29895574 DOI: 10.1158/2326-6066.CIR-17-0270] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 10.3] [Reference Citation Analysis]
194 Mestel D, Beyer M, Steinhoff M, Sterry W. Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 2009;100:18-32. [DOI: 10.1016/s0001-7310(09)73165-5] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
195 Semenov YR, Rosenberg AR, Herbosa C, Mehta-Shah N, Musiek AC. Health-related quality of life and economic implications of cutaneous T-cell lymphoma. Br J Dermatol 2020;182:190-6. [PMID: 30920642 DOI: 10.1111/bjd.17941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
196 Naeini FF, Abtahi-Naeini B, Pourazizi M, Sadeghiyan H, Najafian J. Primary cutaneous lymphomas: A clinical and histological study of 99 cases in Isfahan, Iran. J Res Med Sci 2015;20:827-31. [PMID: 26759567 DOI: 10.4103/1735-1995.170595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
197 Dai W, Wang C, Yu C, Yao J, Sun F, Teng L, Li Y. Preparation of a mixed-matrix hydrogel of vorinostat for topical administration on the rats as experimental model. Eur J Pharm Sci 2015;78:255-63. [PMID: 26248300 DOI: 10.1016/j.ejps.2015.07.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
198 Scarisbrick JJ. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Future Oncology 2017;13:2405-11. [DOI: 10.2217/fon-2017-0263] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
199 Sung JJ, Ververis K, Karagiannis TC. Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. J Photochem Photobiol B 2014;131:104-12. [PMID: 24518645 DOI: 10.1016/j.jphotobiol.2014.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
200 Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol 2013;88:954-60. [PMID: 24474105 DOI: 10.1590/abd1806-4841.20132336] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
201 McCann SA. Cutaneous T-cell lymphoma: overview and nursing perspectives. Nurs Clin North Am 2007;42:421-55, vi-vii. [PMID: 17825663 DOI: 10.1016/j.cnur.2007.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
202 Wu JH, Cohen BA, Sweren RJ. Mycosis fungoides in pediatric patients: Clinical features, diagnostic challenges, and advances in therapeutic management. Pediatr Dermatol 2019;37:18-28. [DOI: 10.1111/pde.14026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
203 Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. Am J Clin Dermatol 2018;19:805-19. [PMID: 30173294 DOI: 10.1007/s40257-018-0380-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
204 Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012;4:471-86. [PMID: 22416775 DOI: 10.4155/fmc.12.6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
205 Iwakura T, Ohashi N, Tsuji N, Naito Y, Isobe S, Ono M, Fujikura T, Tsuji T, Sakao Y, Yasuda H, Kato A, Fujiyama T, Tokura Y, Fujigaki Y. Calcitriol-induced hypercalcemia in a patient with granulomatous mycosis fungoides and end-stage renal disease. World J Nephrol 2013;2:44-8. [PMID: 24175265 DOI: 10.5527/wjn.v2.i2.44] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Smith BD, Wilson LD. Cutaneous Lymphoma. Current Problems in Cancer 2008;32:43-87. [DOI: 10.1016/j.currproblcancer.2007.12.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
207 Semaan S, Abel MK, Raffi J, Murase JE. A clinician's guide to cutaneous T-cell lymphoma presenting as recalcitrant eczematous dermatitis in adults. Int J Womens Dermatol 2021;7:422-7. [PMID: 34621954 DOI: 10.1016/j.ijwd.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Tsianakas A, Kienast A, Hoeger P. Infantile-onset cutaneous T-cell lymphoma. British Journal of Dermatology 2008;159:1338-41. [DOI: 10.1111/j.1365-2133.2008.08794.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
209 Hamada T, Sugaya M, Tokura Y, Ohtsuka M, Tsuboi R, Nagatani T, Tani M, Setoyama M, Matsushita S, Kawai K, Yonekura K, Yoshida T, Saida T, Iwatsuki K. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. J Dermatol 2017;44:135-42. [DOI: 10.1111/1346-8138.13542] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
210 Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal of the American Academy of Dermatology 2013;69:537-43. [DOI: 10.1016/j.jaad.2013.04.063] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
211 Yazganoglu K, Topkarci Z, Buyukbabani N, Baykal C. Childhood mycosis fungoides: a report of 20 cases from Turkey: Childhood mycosis fungoides. Journal of the European Academy of Dermatology and Venereology 2013;27:295-300. [DOI: 10.1111/j.1468-3083.2011.04383.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
212 Iyer JG, Koba S, Nghiem P. Toward better management of merkel cell carcinoma using a consensus staging system, new diagnostic codes and a recently discovered virus. Actas Dermosifiliogr 2009;100 Suppl 2:49-54. [PMID: 20096162 DOI: 10.1016/s0001-7310(09)73378-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
213 Sebastian Mestel D, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opinion on Biological Therapy 2008;8:1929-39. [DOI: 10.1517/14712590802528696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
214 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 16.0] [Reference Citation Analysis]
215 Balagula Y, Dusza SW, Zampella J, Sweren R, Hinds GA. Early-onset mycosis fungoides among African American women: A single-institution study. Journal of the American Academy of Dermatology 2014;71:597-8. [DOI: 10.1016/j.jaad.2014.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]